This article is more than 5 years old. Information may no longer be current.
Top 10 news stories posted in June
Click Here to Manage Email Alerts
Endocrine Today has compiled a list of the top 10 news reports posted during the month of June.
Healio.com/Endocrinology readers were interested in trial results from the American Diabetes Association Scientific Sessions, beta-cell regeneration, how parathyroid hormone and vitamin D can combine to influence atrial fibrillation, and much more.
REWIND: Dulaglutide reduces CV, renal risk in broad type 2 diabetes population
In a large cohort of adults with type 2 diabetes with and without established cardiovascular disease, the once-weekly GLP-1 receptor agonist dulaglutide reduced the risk for nonfatal myocardial infarction, nonfatal stroke and CV death by 12% compared with placebo, according to data from the REWIND study presented at the American Diabetes Association Scientific Sessions.
Maternal HbA1c influences autism risk in offspring
Children born to women with an HbA1c of at least 6.5% were nearly twice as likely to receive a diagnosis of autism in the first 4 years of life vs. offspring of mothers with HbA1c below 5.7%, according to a speaker at the American Diabetes Association Scientific Sessions.
PIONEER: Oral semaglutide proves superior to empagliflozin, noninferior to liraglutide for lowering HbA1c
Favorable results from two PIONEER trials of an oral version of the GLP-1 receptor agonist semaglutide were presented at the American Diabetes Association Scientific Sessions.
In PIONEER 2, oral semaglutide (Novo Nordisk) was associated with superior HbA1c reductions vs. the oral SGLT2 inhibitor empagliflozin (Jardiance, Boehringer Ingelheim) as well as significant weight loss at 52 weeks.
In PIONEER 4, the agent was shown to be noninferior to the injectable GLP-1 receptor agonist liraglutide (Victoza, Novo Nordisk) and superior to placebo in terms of HbA1c reductions, and also superior to both liraglutide and placebo in terms of weight loss at 26 weeks.
New discoveries highlight pathways for beta-cell regeneration in type 1, type 2 diabetes
The promise of beta-cell regeneration — restoring the insulin-producing cells lost in type 1 and type 2 diabetes — has long been considered an ambitious goal. Research now demonstrates that most people with diabetes have residual beta cells with the ability to proliferate; however, researchers have struggled to translate the findings into viable pathways in humans.
CAROLINA: Active-comparator study ‘vindicates’ glimepiride for CV safety
A head-to-head comparison of the sulfonylurea glimepiride against the DPP-IV inhibitor linagliptin in a cohort of more than 6,000 adults with type 2 diabetes demonstrated no between-group differences for incidence of nonfatal myocardial infarction, nonfatal stroke and cardiovascular death during a median of 6 years, according to data from the CAROLINA trial presented at the American Diabetes Association Scientific Sessions.
Elevated parathyroid hormone with low vitamin D may predict atrial fibrillation
Adults with higher parathyroid hormone and lower vitamin D levels are more likely to experience an episode of atrial fibrillation compared with those with normal measures, according to findings published in Nutrition, Metabolism and Cardiovascular Diseases.
Inconsistent sleep behavior heightens metabolic syndrome risk
Adults who frequently change how much sleep they get and the time at which they go to sleep each night are at higher risk for metabolic syndrome compared with those who stick to a consistent sleep regimen, according to findings published in Diabetes Care.
Very severe hypertriglyceridemia tied to diabetes reveals gaps in care
An analysis of county-level health system data in Texas revealed that uncontrolled diabetes often predicted incidence of very severe hypertriglyceridemia, with an overwhelming number of cases occurring among Hispanic adults, according to findings published in the Journal of the Endocrine Society.
Health disparities limit access to diabetes technology
Susan Weiner, MS, RDN, CDE, CDN, FAADE, talks with Diana L. Malkin-Washeim, PhD, MPH, RDN, CDE, who is director of the nutrition and diabetes program in the population health department at BronxCare Health System. The patients Malkin-Washeim works with have the highest poverty and diabetes rates in New York City.
PREVIEW: Intensive weight loss, behavior change prevents conversion to type 2 diabetes
An initial weight loss of at least 8% over 8 weeks using meal replacement products followed by a lifestyle intervention of diet and physical activity markedly reduced the number of new cases of type 2 diabetes in a cohort of adults with prediabetes, according to findings from the PREVIEW study presented at the American Diabetes Association Scientific Sessions.